BACKGROUND: There is no effective second-line systemic chemotherapy for patients with disease progression after cisplatin-based chemotherapy. A phase 2 trial of sorafenib was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen. METHODS: Twenty-seven patients with advanced urothelial carcinoma were treated with sorafenib 400 mg orally twice daily continuously until progression or unacceptable toxicity. RESULTS: There were no objective responses observed. The 4-month progression-free survival (PFS) rate was 9.5%; median overall survival of the group was 6.8 months. There were no therapy-related deaths, and common grade 3 toxicities included fatigue and hand-foot syndrome. CONCLUSIONS: Although sorafenib as a single agent has minimal activity in patients with advanced urothelial cancer in the second-line setting, further investigation of tyrosine kinase inhibitors using different trial designs with PFS endpoints is warranted. Copyright (c) 2009 American Cancer Society.
BACKGROUND: There is no effective second-line systemic chemotherapy for patients with disease progression after cisplatin-based chemotherapy. A phase 2 trial of sorafenib was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen. METHODS: Twenty-seven patients with advanced urothelial carcinoma were treated with sorafenib 400 mg orally twice daily continuously until progression or unacceptable toxicity. RESULTS: There were no objective responses observed. The 4-month progression-free survival (PFS) rate was 9.5%; median overall survival of the group was 6.8 months. There were no therapy-related deaths, and common grade 3 toxicities included fatigue and hand-foot syndrome. CONCLUSIONS: Although sorafenib as a single agent has minimal activity in patients with advanced urothelial cancer in the second-line setting, further investigation of tyrosine kinase inhibitors using different trial designs with PFS endpoints is warranted. Copyright (c) 2009 American Cancer Society.
Authors: D F Bajorin; P M Dodd; M Mazumdar; M Fazzari; J A McCaffrey; H I Scher; H Herr; G Higgins; M G Boyle Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: J A McCaffrey; S Hilton; M Mazumdar; S Sadan; M Heineman; J Hirsch; W K Kelly; H I Scher; D F Bajorin Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: S B Saxman; K J Propert; L H Einhorn; E D Crawford; I Tannock; D Raghavan; P J Loehrer; D Trump Journal: J Clin Oncol Date: 1997-07 Impact factor: 44.544
Authors: K Inoue; J W Slaton; D W Davis; D J Hicklin; D J McConkey; T Karashima; R Radinsky; C P Dinney Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531
Authors: H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544
Authors: A Necchi; P Giannatempo; L Mariani; E Farè; D Raggi; M Pennati; N Zaffaroni; F Crippa; A Marchianò; N Nicolai; M Maffezzini; E Togliardi; M G Daidone; A M Gianni; R Salvioni; F De Braud Journal: Invest New Drugs Date: 2014-02-26 Impact factor: 3.850
Authors: Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo Journal: Clin Genitourin Cancer Date: 2015-03-05 Impact factor: 2.872
Authors: Sanaz Ghafouri; Aaron Burkenroad; Morgan Pantuck; Bara Almomani; Dimitris Stefanoudakis; John Shen; Alexandra Drakaki Journal: World J Urol Date: 2020-05-02 Impact factor: 4.226